UA70340C2 - Optically active 5,6-dihydro-5-[(1-piperidinyl)-meoptically active 5,6-dihydro-5-[(1-piperidinyl)-methyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method fthyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method for the treatment and prevention of vascular diseasor the treatment and prevention of vascular diseases and a pharmaceutical composition es and a pharmaceutical composition - Google Patents

Optically active 5,6-dihydro-5-[(1-piperidinyl)-meoptically active 5,6-dihydro-5-[(1-piperidinyl)-methyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method fthyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method for the treatment and prevention of vascular diseasor the treatment and prevention of vascular diseases and a pharmaceutical composition es and a pharmaceutical composition Download PDF

Info

Publication number: UA70340C2
Authority: UA; Ukraine
Prior art keywords: piperidinyl; pyridyl; oxadiazine; dihydro; methyl
Prior art date: 1998-12-14

Application number

UA2001063850A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-14

Filing date

1999-07-12

Publication date

2004-10-15

1999-07-12 Application filed filed Critical

2004-10-15 Publication of UA70340C2 publication Critical patent/UA70340C2/uk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
208000019553 vascular disease Diseases 0.000 title claims description 9
238000000034 method Methods 0.000 title claims description 7
230000002265 prevention Effects 0.000 title claims description 7
230000002792 vascular Effects 0.000 title claims 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 title abstract 3
239000004480 active ingredient Substances 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims description 17
CEVOFONPLDDUDU-UHFFFAOYSA-N 4-methyl-5-piperidin-1-yl-3-pyridin-3-yl-5,6-dihydro-1,2,4-oxadiazine Chemical compound CN1C(N2CCCCC2)CON=C1C1=CC=CN=C1 CEVOFONPLDDUDU-UHFFFAOYSA-N 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
206010047050 Vascular anomaly Diseases 0.000 claims description 6
239000000463 material Substances 0.000 claims description 5
239000000654 additive Substances 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 3
230000000996 additive effect Effects 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
230000005856 abnormality Effects 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 25
230000001225 therapeutic effect Effects 0.000 abstract description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 16
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
241000700159 Rattus Species 0.000 description 6
239000000829 suppository Substances 0.000 description 6
208000028867 ischemia Diseases 0.000 description 5
230000010412 perfusion Effects 0.000 description 5
208000020446 Cardiac disease Diseases 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
208000019622 heart disease Diseases 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000008101 lactose Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
239000000047 product Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
-1 (-)-5,6-dihydro-5-(1-pyridinyl)-methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine Chemical compound 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
229940110456 cocoa butter Drugs 0.000 description 3
235000019868 cocoa butter Nutrition 0.000 description 3
210000004351 coronary vessel Anatomy 0.000 description 3
239000008298 dragée Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000008753 endothelial function Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000001292 preischemic effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
NNAHNRHEJNQFRI-BTJKTKAUSA-N (Z)-but-2-enedioic acid 4-methyl-5-piperidin-1-yl-3-pyridin-3-yl-5,6-dihydro-1,2,4-oxadiazine Chemical compound OC(=O)\C=C/C(O)=O.CN1C(CON=C1c1cccnc1)N1CCCCC1 NNAHNRHEJNQFRI-BTJKTKAUSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000010247 heart contraction Effects 0.000 description 2
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
230000007574 infarction Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000009090 positive inotropic effect Effects 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
ZNVNHFOAYAMGLK-UHFFFAOYSA-N 4-methyl-5-piperidin-1-yl-3-pyridin-3-yl-5,6-dihydro-1,2,4-oxadiazine;hydrochloride Chemical compound Cl.CN1C(N2CCCCC2)CON=C1C1=CC=CN=C1 ZNVNHFOAYAMGLK-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010065420 Coronary artery dilatation Diseases 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229910021417 amorphous silicon Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
IDAGXRIGDWCIET-SDFKWCIISA-L disodium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IDAGXRIGDWCIET-SDFKWCIISA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000002309 gasification Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
210000001595 mastoid Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
210000003540 papillary muscle Anatomy 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000002594 sorbent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000011699 spontaneously hypertensive rat Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
230000002666 vasoprotective effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UA2001063850A 1998-12-14 1999-07-12 Optically active 5,6-dihydro-5-[(1-piperidinyl)-meoptically active 5,6-dihydro-5-[(1-piperidinyl)-methyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method fthyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method for the treatment and prevention of vascular diseasor the treatment and prevention of vascular diseases and a pharmaceutical composition es and a pharmaceutical composition UA70340C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9802897A HU226617B1 (en)	1998-12-14	1998-12-14	Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
PCT/HU1999/000095 WO2000035914A1 (en)	1998-12-14	1999-12-07	Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (1)

Publication Number	Publication Date
UA70340C2 true UA70340C2 (en)	2004-10-15

Family

ID=10991166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001063850A UA70340C2 (en)	1998-12-14	1999-07-12	Optically active 5,6-dihydro-5-[(1-piperidinyl)-meoptically active 5,6-dihydro-5-[(1-piperidinyl)-methyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method fthyl-3-(3-pyridyl)-4h-1,2,4-oxadiazine, a method for the treatment and prevention of vascular diseasor the treatment and prevention of vascular diseases and a pharmaceutical composition es and a pharmaceutical composition

Country Status (27)

Country	Link
US (1)	US6384029B1 (de)
EP (1)	EP1147105B1 (de)
JP (2)	JP2002532498A (de)
KR (1)	KR100661774B1 (de)
AT (1)	ATE266027T1 (de)
AU (1)	AU765336B2 (de)
BG (1)	BG65179B1 (de)
BR (1)	BR9913982A (de)
CA (1)	CA2340734C (de)
CZ (1)	CZ300764B6 (de)
DE (1)	DE69917074T2 (de)
DK (1)	DK1147105T3 (de)
EE (1)	EE04551B1 (de)
ES (1)	ES2219091T3 (de)
HR (1)	HRP20010133B1 (de)
HU (1)	HU226617B1 (de)
IL (1)	IL141515A (de)
NO (1)	NO317649B1 (de)
PL (1)	PL196584B1 (de)
PT (1)	PT1147105E (de)
RS (1)	RS50129B (de)
RU (1)	RU2222538C2 (de)
SI (1)	SI1147105T1 (de)
SK (1)	SK285582B6 (de)
UA (1)	UA70340C2 (de)
WO (1)	WO2000035914A1 (de)
ZA (1)	ZA200101182B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2471752A1 (en)	2002-01-11	2003-07-17	Biorex Kutato Es Fejlesztoe Rt.	Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) *	2006-09-11	2007-02-06	조만규	가정용 분전함
EP2484371B1 (de)	2008-06-26	2014-12-17	Orphazyme APS	Verwendung von HSP70 als Regler der enzymatischen Aktivität
KR20110084514A (ko)	2008-11-18	2011-07-25	산텐 세이야꾸 가부시키가이샤	피리딘-3-카르발데히드 ｏ-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
RU2013125923A (ru)	2010-11-30	2015-01-10	Орфазиме Апс	СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100534A2 (en)	2011-09-26	2013-04-29	Balazs Dr Hazay	Pharmaceutical composition for the treatment of muscle atrophy
US10709700B2 (en)	2014-09-15	2020-07-14	Orphazyme A/S	Arimoclomol formulation
EP3442530A1 (de)	2016-04-13	2019-02-20	Orphazyme A/S	Hitzeschockproteinen und cholesterinhomöostase
SI3448382T1 (sl)	2016-04-29	2021-03-31	Orphazyme A/S, c/o COBIS A/S	Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
JP2020520947A (ja)	2017-05-24	2020-07-16	オーファザイムエー／エス	熱ショックタンパク質誘導因子および前頭側頭障害
US20210164997A1 (en)	2018-05-28	2021-06-03	Orphazyme A/S	Hsp70 protein levels in pbmc samples as biomarker for disease
WO2022106614A1 (en)	2020-11-19	2022-05-27	Orphazyme A/S	Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT395853B (de) *	1991-01-31	1993-03-25	Chem Pharm Forsch Gmbh	Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) *	1995-11-02	2004-01-28	BIOREX Kutató és Fejlesztő Rt.	Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
WO1997016349A1 (en) *	1995-11-03	1997-05-09	Global Trading Uk Limited	Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) *	1996-08-09	2004-03-15		Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

1998
- 1998-12-14 HU HU9802897A patent/HU226617B1/hu not_active IP Right Cessation
1999
- 1999-07-12 UA UA2001063850A patent/UA70340C2/uk unknown
- 1999-12-07 US US09/762,949 patent/US6384029B1/en not_active Expired - Lifetime
- 1999-12-07 DK DK99961225T patent/DK1147105T3/da active
- 1999-12-07 JP JP2000588174A patent/JP2002532498A/ja not_active Withdrawn
- 1999-12-07 RS YUP-250/01A patent/RS50129B/sr unknown
- 1999-12-07 CA CA002340734A patent/CA2340734C/en not_active Expired - Lifetime
- 1999-12-07 RU RU2001118854/04A patent/RU2222538C2/ru not_active IP Right Cessation
- 1999-12-07 PL PL346767A patent/PL196584B1/pl not_active IP Right Cessation
- 1999-12-07 EE EEP200100188A patent/EE04551B1/xx not_active IP Right Cessation
- 1999-12-07 CZ CZ20011550A patent/CZ300764B6/cs not_active IP Right Cessation
- 1999-12-07 EP EP99961225A patent/EP1147105B1/de not_active Expired - Lifetime
- 1999-12-07 IL IL14151599A patent/IL141515A/xx not_active IP Right Cessation
- 1999-12-07 KR KR1020017002870A patent/KR100661774B1/ko not_active Expired - Fee Related
- 1999-12-07 DE DE69917074T patent/DE69917074T2/de not_active Expired - Lifetime
- 1999-12-07 HR HR20010133A patent/HRP20010133B1/xx not_active IP Right Cessation
- 1999-12-07 AU AU17906/00A patent/AU765336B2/en not_active Expired
- 1999-12-07 PT PT99961225T patent/PT1147105E/pt unknown
- 1999-12-07 SI SI9930566T patent/SI1147105T1/xx unknown
- 1999-12-07 WO PCT/HU1999/000095 patent/WO2000035914A1/en not_active Ceased
- 1999-12-07 SK SK234-2001A patent/SK285582B6/sk not_active IP Right Cessation
- 1999-12-07 BR BR9913982-0A patent/BR9913982A/pt not_active Application Discontinuation
- 1999-12-07 ES ES99961225T patent/ES2219091T3/es not_active Expired - Lifetime
- 1999-12-07 AT AT99961225T patent/ATE266027T1/de active
2001
- 2001-02-12 ZA ZA200101182A patent/ZA200101182B/en unknown
- 2001-03-14 BG BG105342A patent/BG65179B1/bg unknown
- 2001-05-10 NO NO20012310A patent/NO317649B1/no not_active IP Right Cessation
2011
- 2011-06-08 JP JP2011128516A patent/JP5620340B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
BG65179B1 (bg)	2007-05-31
US6384029B1 (en)	2002-05-07
CA2340734C (en)	2008-10-21
AU765336B2 (en)	2003-09-18
SK2342001A3 (en)	2001-08-06
RS50129B (sr)	2009-03-25
JP2002532498A (ja)	2002-10-02
CZ300764B6 (cs)	2009-08-05
HU226617B1 (en)	2009-04-28
HRP20010133A2 (en)	2002-02-28
HUP9802897A2 (hu)	2000-11-28
DE69917074T2 (de)	2005-05-12
KR100661774B1 (ko)	2006-12-28
AU1790600A (en)	2000-07-03
EP1147105A1 (de)	2001-10-24
JP2011201916A (ja)	2011-10-13
EE04551B1 (et)	2005-10-17
NO20012310D0 (no)	2001-05-10
EE200100188A (et)	2002-08-15
IL141515A (en)	2005-09-25
EP1147105B1 (de)	2004-05-06
YU25001A (sh)	2004-07-15
JP5620340B2 (ja)	2014-11-05
KR20010073129A (ko)	2001-07-31
NO20012310L (no)	2001-05-10
RU2222538C2 (ru)	2004-01-27
SI1147105T1 (en)	2004-08-31
ES2219091T3 (es)	2004-11-16
CA2340734A1 (en)	2000-06-22
ATE266027T1 (de)	2004-05-15
HU9802897D0 (en)	1999-02-01
HUP9802897A3 (en)	2001-08-28
BR9913982A (pt)	2001-06-12
NO317649B1 (no)	2004-11-29
PL196584B1 (pl)	2008-01-31
IL141515A0 (en)	2002-03-10
HRP20010133B1 (en)	2005-02-28
DK1147105T3 (da)	2004-06-01
ZA200101182B (en)	2002-02-12
CZ20011550A3 (cs)	2001-08-15
DE69917074D1 (de)	2004-06-09
SK285582B6 (sk)	2007-04-05
PT1147105E (pt)	2004-07-30
PL346767A1 (en)	2002-02-25
BG105342A (en)	2001-12-29
WO2000035914A1 (en)	2000-06-22

Publication	Publication Date	Title
JP5620340B2 (ja)	2014-11-05	光学活性ピリジル−４ｈ−１，２，４−オキサジアジン誘導体およびその血管疾患の治療における使用
JP4316794B2 (ja)	2009-08-19	イソキノリン誘導体及び医薬
JP2011201916A5 (de)	2012-08-02
BR112012007828B1 (pt)	2021-01-12	compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase
CZ333094A3 (en)	1995-09-13	Morpholine and thiomorpholine derivatives, process of their preparation and pharmaceutical composition containing thereof
CN109476635A (zh)	2019-03-15	用于治疗疾病的二取代吡唑类化合物
ES2558677T3 (es)	2016-02-08	Derivado de tetrahidroisoquinolin-1-ona o sal del mismo
CZ62699A3 (cs)	1999-07-14	Heterocyklické inhibitory metaloproteinas
US7550457B2 (en)	2009-06-23	Pharmaceutically effective compounds
US20240336597A1 (en)	2024-10-10	Prodrug of pyrrolidone derivatives as glucokinase activator
BR112016005606B1 (pt)	2020-09-15	Composto, composição farmacêutica, e usos de um composto
KR20220162159A (ko)	2022-12-07	Sstr4 작용제로서의 n-헤테로아릴알킬-2-(헤테로사이클릴 및 헤테로사이클릴메틸)아세트아미드 유도체
JPH01207234A (ja)	1989-08-21	虚血性疾患治療剤および心筋保護剤
CN112759560B (zh)	2022-06-21	含有n-氨基哌嗪片段的苯并噻嗪-4-酮类化合物及其制备方法
HK1232885A (en)	2018-01-19	Compositions of protein receptor tyrosine kinase inhibitors
HK1232885A1 (en)	2018-01-19	Compositions of protein receptor tyrosine kinase inhibitors
ZA200404996B (en)	2006-05-31	Carboxamidine derivatives and their use in the treatment of vascular diseases